This Solicitation opportunity from Department Of Defense was posted on July 27, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
METOPROLOL SUCCINATE E
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The contract is for the procurement of Metoprolol Succinate Extended-Release Tablets, 100 mg, in commercial packaging as specified, with each unit sealed to prevent damage or breakage and packed in suitable shipping containers that ensure safe and cost-effective delivery to the destination. All packaging and labeling must comply with Medical Marking Standard No. 1, which replaces MIL-STD-129, and copies of the standard are available through DLA Troop Support. The item is regulated by the FDA and has a non-extendable shelf life of 36 months. The product is supplied by Teva Pharmaceuticals USA, Inc. with NDC 45963-0677-11 and NSN 6505-01-359-8058, with a quantity of 2 bulk trays (each containing 100 tablets) totaling 200 units. Delivery is required within 20 days to Fort Stewart, Georgia, under FOB destination terms, with no variance allowed in quantity. Inspection and acceptance occur at the destination, and the contract specifies compliance with MIL-STD-2073-1E for packaging. Covered defense information may apply, and the contract is issued under solicitation SPE2DP-26-T-4295 with a response deadline of August 3, 2026. The contracting point of contact is James Mariani of the Department of Defense’s Medical Supply Chain, and the procurement is managed under NAICS code 325412.
General Info
Agency
NAICS
Place of Performance
BLDG 1509 WEST 6TH STREET, FORT STEWART, GA, 31314-5185, USASet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
METOPROLOL SUCCINATE TABLETS, EXTENDED
RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT
RA001: THIS DOCUMENT INCORPORATES TECHNICAL AND/OR QUALITY REQUIREMENTS
(IDENTIFIED BY AN 'R' OR AN 'I' NUMBER) SET FORTH IN FULL TEXT IN THE
DLA MASTER LIST OF TECHNICAL AND QUALITY REQUIREMENTS FOUND ON THE WEB
AT:
http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx
FOR SIMPLIFIED ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE SOLICITATION ISSUE DATE OR THE AWARD DATE CONTROLS. FOR LARGE ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE RFP ISSUE DATE APPLIES UNLESS A SOLICITATION AMENDMENT INCORPORATES A FOLLOW-ON REVISION, IN WHICH CASE THE AMENDMENT DATE CONTROLS.
RQ011: REMOVAL OF GOVERNMENT IDENTIFICATION FROM NON-ACCEPTED SUPPLIES
RELEASE, 100 MG, 100S
APPLICABLE TO ALL MEDICAL ACQUISITIONS:
PACKAGING AND PACKING SHALL BE COMMERCIAL AS
SPECIFIED IN THE PROCUREMENT DOCUMENT.
EACH COMPLETE UNIT SHALL BE PROPERLY PACKAGED
IN A SUITABLE SEALED UNIT CONTAINER CAPABLE
OF PROTECTING THE CONTENTS FROM DAMAGE AND/OR
BREAKAGE.
UNITS SHALL BE PACKED IN SUITABLE COMMERCIAL
EXTERIOR (SHIPPING) CONTAINERS (EXPORT WHEN
NECESSARY) WHICH SHALL INSURE ACCEPTANCE AND
SAFE DELIVERY BY COMMON OR OTHER CARRIER, AT
THE LOWEST RATE, TO POINT OF DELIVERY CALLED
FOR IN THE CONTRACT OR ORDER.
MATERIAL MUST BE MARKED IAW MEDICAL MARKING
STANDARD NO. 1. THIS SUPERCEDES ALL REFERENCES
TO MIL-STD-129.
COPIES OF MEDICAL MARKING STANDARD NO. 1
(MMS NO. 1) MAY BE OBTAINED BY CONTACTING DLA
TROOP SUPPORT VIA EMAIL TO fssb@dla.mil. MMS NO. 1 IS ALSO AVAILABLE ONLINE AT: https://www.dla.mil/Logistics-Operations/Packaging/
1 BT = 100 TT This device or drug is regulated by the FDA. Note to Buyers: The contracting official shall send a referral in EBS to the product specialist for confirmation. Please include bidder name and bidder contact information, manufacturer name, manufacturer part number, and item description. RS020: Shelf-life requirement RS001 for a TYPE I (CODE Q) item with a shelf life of 36 months (non-extendable) applies to this item.
RD003, COVERED DEFENSE INFORMATION POTENTIALLY APPLIES
SPE2DP-26-T-4295
SECTION B
TEVA PHARMACEUTICALS USA, INC. 3V8D7 P/N NDC45963-0677-11
DLA issues this document using the DoD authorized unit of issue, please refer to the following URL to determine the corresponding ANSI X12 unit of issue.
https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.dla.mil%2FPortals%2F104%2FDocuments% 2FDLMS%2FeApplications%2FLogDataAdmin%2FUnitofIssueandPurchaseUnit.xlsx&wdOrigin=BROWSELINK
CLIN PR PRLI UI QUANTITY UNIT PRICE TOTAL PRICE.
0001 7017618333 0001 BT 2.000
NSN/MATERIAL:6505013598058
DELIVERY (IN DAYS):0020
DELIVER FOB: DESTINATION
QTY VARIANCE: PLUS 0% MINUS 0%
INSPECTION POINT: DESTINATION
ACCEPTANCE POINT: DESTINATION
PREP FOR DELIVERY:
PKGING DATA MIL-STD-2073-1E
SPECIAL NSN/Part Number: 6505-01-359-8058 Quantity: 2 BT Purchase Request: 7017618333QTY: 2 Delivery: 20 days ADO
More opportunities from Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
Same awarding agency
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 650+ contractors already using CLEATUS